Type 2 Diabetes Mellitus Clinical Trial
Official title:
A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin
| Verified date | April 2009 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral antidiabetic agents in addition to diet and lifestyle advice). The study comprises a 3-week enrollment period and a 24-week randomized, double blind, multi-center, placebo-controlled treatment period and a 3-week follow-up. Patients must receive at least 30 units of insulin per day and will continue their current oral antidiabetic treatment regimen throughout the study.
| Status | Terminated |
| Enrollment | 370 |
| Est. completion date | March 2006 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Provision of a written informed consent - Men or women who are >=18 years of age - Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control - Diagnosed with type 2 diabetes for less than 20 years and receiving at least 30 U insulin per day Exclusion Criteria: - Type 1 diabetes - New York Heart Association heart failure Class III or IV - Treatment with any thiazolidinedione class of antidiabetic agents - History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) - History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) - Creatinine levels above twice the normal range - Creatine kinase above 3 times the upper limit of normal - Received any investigational product in other clinical studies within 12 weeks - Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | Research Site | Albuquerque | New Mexico |
| United States | Research Site | Altoona | Pennsylvania |
| United States | Research Site | Augusta | Georgia |
| United States | Research Site | Baltimore | Maryland |
| United States | Research Site | Bellevue | Washington |
| United States | Research Site | Bethesda | Maryland |
| United States | Research Site | Birmingham | Alabama |
| United States | Research Site | Boise | Idaho |
| United States | Research Site | Brooklyn | New York |
| United States | Research Site | Cadillac | Michigan |
| United States | Research Site | Charlotte | North Carolina |
| United States | Research Site | Cheswick | Pennsylvania |
| United States | Research Site | Chicago | Illinois |
| United States | Research Site | Chicago Heights | Illinois |
| United States | Research Site | Cincinnati | Ohio |
| United States | Research Site | Columbia | South Carolina |
| United States | Research Site | Corpus Christie | Texas |
| United States | Research Site | Dallas | Texas |
| United States | Research Site | Dover | New Hampshire |
| United States | Research Site | Dunwoody | Georgia |
| United States | Research Site | Erie | Pennsylvania |
| United States | Research Site | Fort Worth | Texas |
| United States | Research Site | Fresno | California |
| United States | Research Site | Gainesville | Florida |
| United States | Research Site | Greenbrae | California |
| United States | Research Site | Greer | South Carolina |
| United States | Research Site | Gurnee | Illinois |
| United States | Research Site | Hollywood | Florida |
| United States | Research Site | Houston | Texas |
| United States | Research Site | Indianapolis | Indiana |
| United States | Research Site | Jacksonville | Florida |
| United States | Research Site | Kettering | Ohio |
| United States | Research Site | La Jolla | California |
| United States | Research Site | Madison | Wisconsin |
| United States | Research Site | Maywood | Illinois |
| United States | Research Site | Medford | Oregon |
| United States | Research Site | Miami | Florida |
| United States | Research Site | New Hyde Park | New York |
| United States | Research Site | New Orleans | Louisiana |
| United States | Research Site | North Las Vegas | Nevada |
| United States | Research Site | Northridge | California |
| United States | Research Site | Oklahoma City | Oklahoma |
| United States | Research Site | Omaha | Nebraska |
| United States | Research Site | Orlando | Florida |
| United States | Research Site | Pahrump | Nevada |
| United States | Research Site | Palm Harbor | Florida |
| United States | Research Site | Philadelphia | Pennsylvania |
| United States | Research Site | Phoenix | Arizona |
| United States | Research Site | Portland | Oregon |
| United States | Research Site | Renton | Washington |
| United States | Research Site | Richmond | Virginia |
| United States | Research Site | Richmond Heights | Missouri |
| United States | Research Site | Riverside | California |
| United States | Research Site | Roseland | New Jersey |
| United States | Research Site | San Antonio | Texas |
| United States | Research Site | San Diego | California |
| United States | Research Site | Santa Monica | California |
| United States | Research Site | Spokane | Washington |
| United States | Research Site | Spring Valley | California |
| United States | Research Site | Springfield | Illinois |
| United States | Research Site | St Louis | Missouri |
| United States | Research Site | Tacoma | Washington |
| United States | Research Site | Toledo | Ohio |
| United States | Research Site | Tuscson | Arizona |
| United States | Research Site | Walnut Creek | California |
| United States | Research Site | Washington | District of Columbia |
| United States | Research Site | Waterbury | Connecticut |
| United States | Research Site | West Hills | California |
| United States | Research Site | West Palm Beach | Florida |
| United States | Research Site | Wichita | Kansas |
| United States | Research Site | Wilmington | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c) | |||
| Secondary | Changes in the following variables from baseline to the end of the randomized treatment period: | |||
| Secondary | The change in fasting plasma glucose (FPG), insulin, proinsulin and C-peptide from baseline to the end of the randomized treatment period | |||
| Secondary | Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model from baseline to the end of the randomized treatment period | |||
| Secondary | Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c | |||
| Secondary | C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio | |||
| Secondary | FPG, homeostasis assessment model, insulin, proinsulin, C-peptide | |||
| Secondary | Tumor necrosis factor-alpha, intracellular adhesion molecule-1 | |||
| Secondary | Fibrinogen | |||
| Secondary | Urinary albumin excretion | |||
| Secondary | Waist/hip ratio | |||
| Secondary | Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values | |||
| Secondary | Proportion of patients reaching pre-specified target levels for HbA1c, FPG, TG, HDL C, non-HDL C and LDL C | |||
| Secondary | Pharmacokinetics of tesaglitazar | |||
| Secondary | Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination | |||
| Secondary | To validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI-Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) in patients with type 2 diabetes and to explore the effects of tesaglitazar (0.5 mg) on pati |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |